BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia
December 24, 2025
Source: drugdu
31
On December 23, 2025, BeiGene announced the initiation of a global, multicenter Phase II clinical trial of catadegbrutinib (BTK, PROTAC) for B-cell hematologic malignancies. The trial, designated CTR20254960, is titled "Evaluating BGB-16673, a Bruton's tyrosine kinase-targeting protein degrader, in a Phase 1/2, open-label, dose-escalation and expansion study for the treatment of patients with B-cell malignancies." This international, multicenter clinical trial plans to enroll 730 participants.
The investigational drug in this clinical trial is catadegbrutinib.
The primary endpoint was the major response rate (MRR) in stage II.
The domestic lead institution is Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and the principal investigator is Professor Li Jian.
https://bydrug.pharmcube.com/news/detail/55a4c0369a540aa555859fb702eea4f7
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Over $2 billion! Another major deal for a domestically developed innovative drug December 24, 2025
- Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia December 24, 2025
- IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA December 24, 2025
- Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP) December 24, 2025
- Subsidiary Receives Clinical Trial Approval for Daratumumab Injection December 24, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
